Oramed Pharmaceuticals (ORMP) Proxy filing summary

Executive summary

• Annual Meeting scheduled for August 19, 2025, with proposals to re-elect seven directors, ratify the independent auditor, and amend the 2019 Stock Incentive Plan.

• Record date for voting is July 3, 2025; proxy materials distributed to all eligible shareholders.

• Board unanimously recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Shareholders will vote on re-election of seven directors, ratification of Kesselman & Kesselman as auditor, and an amendment to increase shares under the 2019 Stock Incentive Plan by 2,000,000.

• All proposals require a majority of votes cast to pass.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of seven members, all nominated for re-election; five are independent under Nasdaq rules.

• Board committees include Audit, Compensation, Nominating, and Investment Committees, all with defined charters and responsibilities.

• Annual board and committee evaluations are conducted for continuous improvement.

• Directors serve one-year terms and may be re-elected annually.